SCHEMBL6002068

SCHEMBL6002068

CCOC(=O)c1c(S(=O)(=O)/N=N/C)c2cc(Cl)ccc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 3/20 0.48
NOD1 Q9Y239 3/20 0.48
ACLY P53396 1/20 0.45
PSEN1 P49768 2/20 0.43
PSEN2 P49810 2/20 0.43
APH1B Q8WW43 2/20 0.43
NCSTN Q92542 2/20 0.43
APH1A Q96BI3 2/20 0.43
PSENEN Q9NZ42 2/20 0.43
ALDH1A1 P00352 4/20 0.40
PPARG P37231 3/20 0.40
PPARA Q07869 3/20 0.40
PPARD Q03181 2/20 0.40
PTGDR Q13258 2/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.40
HTR6 P50406 2/20 0.40
HPGD P15428 2/20 0.39
ELANE P08246 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6002074 1.00 NOD2 (0.48) NOD2NOD1ACLYPSEN1PSEN2
SCHEMBL2346812 0.89 NOD2 (0.52) NOD2NOD1ACLYPSEN1PSEN2
SCHEMBL2345728 0.87 NOD2 (0.52) NOD2NOD1ACLYPSEN1PSEN2
SCHEMBL2351246 0.86 NOD2 (0.51) NOD2NOD1ACLYPSEN1PSEN2
SCHEMBL2346815 0.85 NOD2 (0.49) NOD2NOD1ACLYPSEN1PSEN2
SCHEMBL2005697 0.83 NOD2 (0.53) NOD2NOD1ACLYPSEN1PSEN2
SCHEMBL2540534 0.82 NOD2 (0.53) NOD2NOD1ACLYPSEN1PSEN2
SCHEMBL2929041 0.81 SMN1; SMN2 (0.47) NOD2NOD1ACLYALDH1A1PTGDR2
SCHEMBL8938302 0.80 MAPT (0.50) NOD2NOD1ACLYPSEN1PSEN2
SCHEMBL12228548 0.80 NOD2 (0.50) NOD2NOD1ACLYPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060128783-A1 Tyrosine kinase inhibitors DINSMORE CHRISTOPHER J 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128783-A1 Tyrosine kinase inhibitors ABL1, ERBB2, JAK2 NOD2 2323/4885NOD1 1661/4885ACLY 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.